Navigation Links
Response time to open arteries for most critical patients still too slow
Date:11/16/2011

HOUSTON (Nov. 16, 2011) Cardiologists are quick to point to statistics showing that the "door-to-balloon" treatment time for heart attack patients has dropped significantly in the past few years.

But a retrospective study reveals that those who call 911 are most likely to have suffered a severe heart attack and despite receiving treatment quickly, they are still dying at unacceptable rates, say researchers at The University of Texas Health Science Center at Houston (UTHealth).

Results from the large retrospective study were presented yesterday at the American Heart Association's Scientific Sessions 2011 by lead author James J. McCarthy, M.D., assistant professor of emergency medicine at the UTHealth Medical School and director of the Emergency Center at Memorial Hermann-Texas Medical Center.

Door-to-balloon refers to the period of time from a patient's arrival at the hospital to when a guidewire reaches the blockage and opens the artery with the inflation of a tiny balloon.

The results of the study revealed that patients who call 911 instead of transporting themselves to the emergency room arrive 30 minutes faster and have shorter door-to-balloon times (56 minutes versus 70). Unfortunately, in spite of this they are more likely to be in shock (10.7 percent versus 3.5), suffer heart failure (9.9 percent versus 6.3) by the time they get to the hospital and more likely to die during their hospitalization (7.2 percent versus 2.4).

"Those who call an ambulance are three times more likely to die because their disease is worse. They are much sicker," McCarthy said. "We suspect that it means they have a larger infarct (area of damage). It's a vulnerable population that despite rapid emergency medical services (EMS) and hospital care still has higher mortality"

Previous UTHealth research has shown that if the artery is unblocked in the first hour after a heart attack, there is minimal damage. After three hours, most of the damage has been done so UTHealth researchers have been concentrating on how to shorten that time to two hours or less.

The only way to lower the current time from symptoms to opening the artery is to treat the patient in the ambulance, McCarthy said. A year ago he presented results of a UTHealth clinical trial called Pre-Hospital Administration of Thrombolytic Therapy with Urgent Culprit Artery Revascularization (PATCAR). That trial showed that the mortality rate of patients arriving via EMS could be lowered to 2.9 percent by giving them a low dose of a clot-busting drug intravenously before they arrived at the hospital. The research was a collaboration of UTHealth, Memorial Hermann Heart & Vascular Institute-Texas Medical Center (HVI) and the Houston Fire Department.

"We know we've optimized the hospital system and integrated that with EMS but for the cohort that calls 911, that's still not enough," he said. "We need to figure out something else." The researchers are seeking additional funding to expand PATCAR to more patients.

The researchers looked at 37,715 patients in the American College of Cardiology's National Cardiovascular Data Registry. The presentation title is "EMS Transport of STEMI Patients Shortens Ischemic Times and is Associated with a Higher Risk Population: Results from the ACTION Registry."


'/>"/>

Contact: Deborah Mann Lake
deborah.m.lake@uth.tmc.edu
University of Texas Health Science Center at Houston
Source:Eurekalert

Related medicine news :

1. Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
2. Study identifies factors linked with better medication response for treatment of juvenile arthritis
3. Gladstone scientists identify gene critical for cell responses to oxygen deprivation
4. MVA-B Spanish HIV vaccine shows 90 percent immune response in humans
5. Chemo plus radiation before surgery increases tumor response for rectal cancer
6. Decoding vaccination: Mayo researchers reveal genetic underpinnings of response to measles vaccine
7. Childhood maltreatment linked to long-term depression risk and poor response to treatment
8. Fatty Comfort Foods May Alter Brains Response to Sadness
9. Signaling molecule identified as essential for maintaining a balanced immune response
10. Low Empathy Response in Brain Might Point to Autism Gene
11. Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management ... radiology marketing programs at the annual Building Better Radiology Marketing Programs conference, ... Hotel in Fort Worth, Texas. Nine awards are given out in five categories. They ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
Breaking Medicine Technology: